Smith & Nephew (LON:SN) Hits New 52-Week High – Here’s What Happened

Smith & Nephew plc (LON:SN) shares reached a new 52-week high on Friday . The stock traded as high as GBX 1,255.77 and last traded at GBX 1,242, with a volume of 3248581 shares traded. The stock had previously closed at GBX 1,213.50.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on SN shares. Panmure Gordon restated a “hold” rating and issued a GBX 1,200 price objective on shares of Smith & Nephew in a research report on Tuesday, December 9th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and decreased their target price for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a research report on Friday, January 23rd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Finally, Citigroup raised their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Smith & Nephew currently has a consensus rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Stock Up 2.3%

The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The company has a market capitalization of £13.62 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 0.46 and a beta of 0.62. The firm has a 50-day moving average price of GBX 1,234.78 and a two-hundred day moving average price of GBX 1,287.49.

Insiders Place Their Bets

In other news, insider Deepak Nath sold 1,240 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is currently owned by company insiders.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.